Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
J&J in talks to acquire eye disease biotech for up to $3.4bn
00

J&J in talks to acquire eye disease biotech for up to $3.4bn

Nov 15, 2026

Johnson & Johnson is in talks to acquire Texas-based biotech startup Ollin Biosciences for up to $3.4 billion, including $2.2 billion in upfront cash and $1.2 billion in potential milestone payments. The deal would provide Johnson & Johnson entry into retinal disease therapies via Ollin's lead phase-three drug candidate, OLN324, which targets wet age-related macular degeneration and diabetic macular edema. The acquisition follows J&J's recent multi-billion dollar buyouts of Firefly Bio and Intra-Cellular Therapies amid record biotech deal volumes in 2026.

Acquisition terms and deal structure

  • ▪Johnson & Johnson is in discussions to acquire privately held Texas-based drug developer Ollin Biosciences for up to $3.4 billion
  • ▪Johnson & Johnson could announce the acquisition of Ollin Biosciences as early as November 16, 2026, though people familiar with the matter cautioned talks could still collapse
  • ▪Under proposed terms, Johnson & Johnson would pay Ollin Biosciences' backers $2.2 billion in upfront cash and up to $1.2 billion in potential future milestone payments

Ollin Biosciences drug pipeline and funding

  • ▪Ollin Biosciences raised $330 million in June 2026 to fund late-stage clinical trials for its experimental drug OLN324
  • ▪Ollin Biosciences is backed by investment firms Arch Venture Partners, Mubadala Capital, TCGX, RA Capital, and Monograph Capital
  • ▪Ollin Biosciences' lead experimental drug, OLN324, is being developed to treat wet age-related macular degeneration and diabetic macular edema

Biotech industry M&A trends in 2026

  • ▪According to investment bank Stifel, a record 46 biotech companies valued at over $1 billion have been acquired so far in 2026, surpassing the prior annual record of 35
  • ▪Biotechnology sector dealmaking reached $131.5 billion in the first half of 2026 before slowing to $44.8 billion in the second half of the year to date

Other recent Johnson & Johnson acquisitions

  • ▪Johnson & Johnson purchased psychiatric drugmaker Intra-Cellular Therapies for $14.6 billion at the start of 2025 to expand its neurological disorder business
  • ▪Johnson & Johnson acquired oncology drug developer Firefly Bio earlier in 2026 in a transaction valued at $1 billion in cash

Expansion into eye disease treatments

  • ▪Acquiring Ollin Biosciences would give Johnson & Johnson entry into retinal disease treatments, an area where the drugmaker currently has limited presence despite its contact lens business
  • ▪Pharmaceutical companies including Merck and Bayer have expanded into eye disease medicines in recent years by buying early-stage companies

2 sources

Reuters
J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says | Reuters
View source article
Financial Times
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
View source article

Featured stories

View more in Wet AMD

US and allies agree to jointly guard AI supply chains from China

Nov 15, 2026 · 4 sources

Nscale discloses ballooning debt and Nvidia financing dependence ahead of IPO

Nov 12, 2026 · 4 sources

SpaceX plans $74 billion data center buildout in Texas and Arizona

Nov 12, 2026 · 3 sources

TSMC to invest $1 billion in Anthropic and OpenAI

Nov 11, 2026 · 4 sources

Story comments

Loading comments…

Related entities

Merck

Related Projects

Johnson & Johnson

Topics

Wet AMDMergers & acquisitions (M&A)Macular edema treatmentMergers and acquisitionsFinancial tiesPharmaceutical IndustryBiotech innovationTexasDrug development

Featured stories

View more in Wet AMD

US and allies agree to jointly guard AI supply chains from China

Nov 15, 2026 · 4 sources

Nscale discloses ballooning debt and Nvidia financing dependence ahead of IPO

Nov 12, 2026 · 4 sources

SpaceX plans $74 billion data center buildout in Texas and Arizona

Nov 12, 2026 · 3 sources

TSMC to invest $1 billion in Anthropic and OpenAI

Nov 11, 2026 · 4 sources